The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Prostatic Diseases

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Prostatic Diseases

  • Individuals without prostatic diseases (n = 92) had values for serum PAP activity up to 0.36 U/L (0.94 microgram/L), in an age-independent distribution; patients with benign prostatic hyperplasia (n = 62) showed values up to 0.48 U/L (1.25 micrograms/L) [1].
  • PURPOSE: We evaluated positron emission tomograph (PET) with 18fluorine (18F)-labeled deoxyglucose for metabolic grading of untreated primary prostate cancer, and differentiation of benign and malignant prostatic disease [2].
  • Using the developmentally estrogenized mouse model, we propose an alternative role for estrogens as a predisposing factor for prostatic diseases: estrogen exposure during development may initiate cellular changes in the prostate which would require estrogens and/or androgens later in life for promotion to hyperplasia or neoplasia [3].
  • In order to investigate the relationship between bone metastases and alpha 2M, we assessed these two parameters in 128 patients with prostatic diseases [4].
  • 5. The levels of PASP in peripheral serum were less than 0.1 mg/L in normal subjects, 0.7-3 mg/L in cases of acute pancreatitis, and less than 0.1 mg/L in cases of pancreatic carcinoma, prostatic diseases, and other abdominal diseases investigated [5].

High impact information on Prostatic Diseases

  • Prostate-specific antigen (PSA) is the most important of all tumor markers in that it has significant applications in all aspects of the management of men with prostatic disease [6].
  • In addition to highlighting the regulatory role of androgens and TGF-beta, these findings may have important implications for the deregulation of the stem cell compartment in the etiology of proliferative prostatic diseases [7].
  • Furthermore, the clinical safety of androgen therapy for cardiovascular and prostatic disease is uncertain [8].
  • The results suggest that the codon10 polymorphism in TGFB1 may have a significant influence on the development of PCa and BPH, therefore underscoring the importance of the TGF pathway in the development of these prostatic diseases [9].
  • Citrate and choline resonances alone are not sufficiently accurate markers for distinguishing between various patterns of prostatic disease [10].

Chemical compound and disease context of Prostatic Diseases

  • On the other hand, sera from patients with above-normal alkaline phosphatase activity and no prostatic disease showed little or no activity on phosphotyrosine at both acid and alkaline pH values [11].
  • BACKGROUND: The known importance of the endocrine system, particularly of steroid hormones, for development of the prostate gland and the fact that steroid hormones act as immunmodulators prompted us to compare hypophyseal, adrenal, and gonadal hormones, including cortisol, in patients with benign and malignant prostatic diseases [12].
  • Patients with malignant prostatic disease also had a significantly higher concentration of oleic acid in phospholipids from both plasma and prostatic tissue [13].
  • Casodex has the potential to become an important drug for treatment of prostatic diseases [14].
  • All had their serum prostate-specific antigen (PSA) analysed and those referred for investigation of prostatic disease underwent serum testosterone analysis [15].

Biological context of Prostatic Diseases


Anatomical context of Prostatic Diseases

  • Prostate-specific antigen (PSA) is secreted exclusively by prostatic epithelial cells, and its serum concentration is increased in men with prostatic disease, including cancer [20].
  • In normal, hypertrophic, and neoplastic prostate glands, beta-microseminoprotein was found in glandular epithelium but not in stroma cells. beta-Microseminoprotein may be as useful as gamma-seminoprotein in the pathologic examination of prostatic diseases, especially in histogenic classification of tumors or metastatic tumors [21].
  • In the context of searching for a noninvasive, highly reliable method for prostate cancer diagnosis, we assessed the extent to which extracellular (ie, surface-bound) and intracellular PSA-positive macrophages might differentiate patients with benign versus malignant prostatic disease [22].

Gene context of Prostatic Diseases


Analytical, diagnostic and therapeutic context of Prostatic Diseases

  • METHODS: Tissue was collected prospectively from 46 patients with BPH who underwent TURP for clinically benign prostatic disease, and who were examined using the telomeric repeat amplification protocol (TRAP assay) [27].
  • Patient samples consisted of 55 untreated histologically confirmed primary cancer, 62 men with untreated benign prostatic disease histologically confirmed by 6 negative sextant biopsies, and 64 asymptomatic healthy male controls with normal digital rectal examinations and PSA values less than 4.0 ng/mL [28].
  • Hormonal dependency of prostate cancer was first described in 1895 by White who showed the initial observation between castration and the treatment of prostatic disease in men with bladder outlet obstruction secondary to benign prostatic hypertrophy [29].
  • A fluorescent artefact resembling BB-creatine kinase in sera of patients with prostatic disease [30].
  • MATERIALS AND METHODS: Each assay was evaluated against a panel of serum samples comprising those from patients with prostatic disease, other malignancies, normal subjects and sera containing substances which might interfere with the immunoassay [31].


  1. Development and evaluation of a new solid-phase direct immunoenzyme assay for prostatic acid phosphatase. Gericke, K., Kohse, K.P., Pfleiderer, G., Flüchter, S.H., Bichler, K.H. Clin. Chem. (1982) [Pubmed]
  2. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. Effert, P.J., Bares, R., Handt, S., Wolff, J.M., Büll, U., Jakse, G. J. Urol. (1996) [Pubmed]
  3. Developmental estrogenization and prostatic neoplasia. Santti, R., Newbold, R.R., Mäkelä, S., Pylkkänen, L., McLachlan, J.A. Prostate (1994) [Pubmed]
  4. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer. Kanoh, Y., Ohtani, N., Mashiko, T., Ohtani, S., Nishikawa, T., Egawa, S., Baba, S., Ohtani, H. Anticancer Res. (2001) [Pubmed]
  5. A novel serum assay for pancreatic cellular damage. II. High tissue specificity of a pancreatic protein. Pousette, A., Fernstad, R., Sköldefors, H., Carlström, K. Pancreas (1988) [Pubmed]
  6. Prostate-specific antigen: current status. Brawer, M.K. CA: a cancer journal for clinicians. (1999) [Pubmed]
  7. TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. Salm, S.N., Burger, P.E., Coetzee, S., Goto, K., Moscatelli, D., Wilson, E.L. J. Cell Biol. (2005) [Pubmed]
  8. Clinical review 171: The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. Liu, P.Y., Swerdloff, R.S., Veldhuis, J.D. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
  9. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Li, Z., Habuchi, T., Tsuchiya, N., Mitsumori, K., Wang, L., Ohyama, C., Sato, K., Kamoto, T., Ogawa, O., Kato, T. Carcinogenesis (2004) [Pubmed]
  10. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Swindle, P., McCredie, S., Russell, P., Himmelreich, U., Khadra, M., Lean, C., Mountford, C. Radiology. (2003) [Pubmed]
  11. Prostatic acid phosphatase in serum of patients with prostatic cancer is a specific phosphotyrosine acid phosphatase. Nguyen, L., Chapdelaine, A., Chevalier, S. Clin. Chem. (1990) [Pubmed]
  12. Endocrine patterns in patients with benign and malignant prostatic diseases. Schatzl, G., Reiter, W.J., Thürridl, T., Waldmüller, J., Roden, M., Söregi, S., Madersbacher, S. Prostate (2000) [Pubmed]
  13. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Chaudry, A., McClinton, S., Moffat, L.E., Wahle, K.W. Br. J. Cancer (1991) [Pubmed]
  14. Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. Eri, L.M., Urdal, P. Eur. Urol. (1995) [Pubmed]
  15. An investigation of erectile dysfunction in Gwent, Wales. Green, J.S., Holden, S.T., Ingram, P., Bose, P., St George, D.P., Bowsher, W.G. BJU international. (2001) [Pubmed]
  16. Altered prostatic epithelial proliferation and apoptosis, prostatic development, and serum testosterone in mice lacking cyclin-dependent kinase inhibitors. Mukai, M., Dong, Q., Hardy, M.P., Kiyokawa, H., Peterson, R.E., Cooke, P.S. Biol. Reprod. (2005) [Pubmed]
  17. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Shah, U.S., Dhir, R., Gollin, S.M., Chandran, U.R., Lewis, D., Acquafondata, M., Pflug, B.R. Hum. Pathol. (2006) [Pubmed]
  18. Analysis of G/A polymorphism in the androgen response element I of the PSA gene and its interactions with the androgen receptor polymorphisms. Rao, A., Chang, B.L., Hawkins, G., Hu, J.J., Rosser, C.J., Hall, M.C., Meyers, D.A., Xu, J., Cramer, S.D. Urology (2003) [Pubmed]
  19. Effect of epristeride on the expression of IGF-1 and TGF-beta receptors in androgen-induced castrated rat prostate. Wu, S.F., Sun, H.Z., Qi, X.D., Tu, Z.H. Exp. Biol. Med. (Maywood) (2001) [Pubmed]
  20. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. Catalona, W.J., Smith, D.S., Ratliff, T.L., Dodds, K.M., Coplen, D.E., Yuan, J.J., Petros, J.A., Andriole, G.L. N. Engl. J. Med. (1991) [Pubmed]
  21. Ultrastructural localizations of beta-microseminoprotein, a prostate-specific antigen, in human prostate and sperm: comparison with gamma-seminoprotein, another prostate-specific antigen. Ito, Y., Tsuda, R., Kimura, H. J. Lab. Clin. Med. (1989) [Pubmed]
  22. Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. Herwig, R., Pelzer, A., Horninger, W., Rehder, P., Klocker, H., Ramoner, R., Pinggera, G.M., Gozzi, C., Konwalinka, G., Bartsch, G. Clinical prostate cancer. (2004) [Pubmed]
  23. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Becker, C., Noldus, J., Diamandis, E., Lilja, H. Critical reviews in clinical laboratory sciences. (2001) [Pubmed]
  24. The role of PTEN in the progression and survival of prostate cancer. Deocampo, N.D., Huang, H., Tindall, D.J. Minerva Endocrinol. (2003) [Pubmed]
  25. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases. Zhang, W.M., Finne, P., Leinonen, J., Stenman, U.H. Scand. J. Clin. Lab. Invest. Suppl. (2000) [Pubmed]
  26. Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: a comparative evaluation. Dejter, S.W., Martin, J.S., McPherson, R.A., Lynch, J.H. Urology (1988) [Pubmed]
  27. An appraisal of telomerase activity in benign prostatic hyperplasia. Caldarera, E., Crooks, N.H., Muir, G.H., Pavone-Macaluso, M., Carmichael, P.L. Prostate (2000) [Pubmed]
  28. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Luderer, A.A., Chen, Y.T., Soriano, T.F., Kramp, W.J., Carlson, G., Cuny, C., Sharp, T., Smith, W., Petteway, J., Brawer, M.K. Urology (1995) [Pubmed]
  29. Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate. Lawton, C.A. Seminars in radiation oncology. (2003) [Pubmed]
  30. A fluorescent artefact resembling BB-creatine kinase in sera of patients with prostatic disease. Jaggarao, N., Moss, D.W. Clin. Chim. Acta (1979) [Pubmed]
  31. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA. Patel, D., White, P.A., Milford Ward, A. BJU international. (2000) [Pubmed]
WikiGenes - Universities